Impact of pre-exposure prophylaxis uptake among gay, bisexual, and other men who have sex with men in urban centers in Brazil: a modeling study

[21] Szwarcwald CL(2014)CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis AIDS 28 223-950

[22] Ferreira Oda CJ(2015)Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis J Infect Dis 212 754-1099

[23] Brito AM(2018)Effectiveness of antiretroviral therapy in the single-tablet regimen era Rev Saude Publica 52 87-287

[24] Luhm KR(2017)Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Lancet 390 2073-2691

[25] Ribeiro CE(2019)Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial Lancet HIV 6 e364-57

[26] Silva AM(2012)Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings BMC Infect Dis 12 147-340

[27] Cavalcanti AM(2018)Sociodemographic determinants of attrition in the HIV continuum of care in Brazil, in 2016 Medicine (Baltimore) 97 S69-e268

[28] Ito TS(2018)Maximizing the benefits of HIV preexposure prophylaxis Top Antivir Med 25 138-undefined

[29] Raboni SM(2019)Global implementation of PrEP for HIV prevention: setting expectations for impact J Int AIDS Soc 22 e25370-undefined

[30] Souza PRJ(2019)Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: results from the PrEP Brasil Study PLoS ONE 14 e0221281-undefined

[21] Szwarcwald CL(2014)CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis AIDS 28 223-950

[22] Ferreira Oda CJ(2015)Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis J Infect Dis 212 754-1099

[23] Brito AM(2018)Effectiveness of antiretroviral therapy in the single-tablet regimen era Rev Saude Publica 52 87-287

[24] Luhm KR(2017)Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Lancet 390 2073-2691

[25] Ribeiro CE(2019)Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial Lancet HIV 6 e364-57

[26] Silva AM(2012)Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings BMC Infect Dis 12 147-340

[27] Cavalcanti AM(2018)Sociodemographic determinants of attrition in the HIV continuum of care in Brazil, in 2016 Medicine (Baltimore) 97 S69-e268

[28] Ito TS(2018)Maximizing the benefits of HIV preexposure prophylaxis Top Antivir Med 25 138-undefined

[29] Raboni SM(2019)Global implementation of PrEP for HIV prevention: setting expectations for impact J Int AIDS Soc 22 e25370-undefined

[30] Souza PRJ(2019)Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: results from the PrEP Brasil Study PLoS ONE 14 e0221281-undefined